DiaSorin SpA/ADR
No enriched coverage for $DSRNY in the last 7 days.
No SEC Form 4 filings for $DSRNY in the last 30 days.
See all $DSRNY insider activity →UBS downgraded DiaSorin SpA to “sell” from “neutral” and cut its price target to €55 from €66, citing Roche competition and expectations that Immunodiagnostics and Molecular growth have outpaced competitive reality. UBS estimates adjusted EBIT 2026-27 are 4%-6% below consensus and forecasts lower EPS and revenue growth.
DiaSorin shares fell 3.8% to €73.68 after UBS downgraded the stock to “sell” from “neutral” and cut its price target by about 17% to €55. UBS cited rising competition and China policy headwinds in immunodiagnostics, plus execution risk for DiaSorin’s Liaison Nes platform in molecular diagnostics. UBS expects 2026 EBIT 4% to 6% below consensus.
Simply Wall St reports DiaSorin S.p.A. Q2 2026 sales of €315 million and net income of €46 million, broadly in line with the prior year. H1 2026 sales were €602 million and net income €84 million, down year on year. The article also cites a buyback program up to €250 million and discusses analyst expectations for 2029.
Recent DSRNY coverage spans market movers and earnings.
UBS downgraded DiaSorin SpA to “sell” from “neutral” and cut its price target to €55 from €66, citing Roche competition and expectations that Immunodiagnostics and Molecular growth have outpaced competitive reality. UBS estimates adjusted EBIT 2026-27 are 4%-6% below consensus and forecasts lower EPS and revenue growth.
DiaSorin shares fell 3.8% to €73.68 after UBS downgraded the stock to “sell” from “neutral” and cut its price target by about 17% to €55. UBS cited rising competition and China policy headwinds in immunodiagnostics, plus execution risk for DiaSorin’s Liaison Nes platform in molecular diagnostics. UBS expects 2026 EBIT 4% to 6% below consensus.
Simply Wall St reports DiaSorin S.p.A. Q2 2026 sales of €315 million and net income of €46 million, broadly in line with the prior year. H1 2026 sales were €602 million and net income €84 million, down year on year. The article also cites a buyback program up to €250 million and discusses analyst expectations for 2029.
alphai scores every news story that mentions DSRNY with an AI model for sentiment and relevance, and aggregates insider trades from DiaSorin SpA/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS downgraded DiaSorin SpA to “sell” from “neutral” and cut its price target to €55 from €66, citing Roche competition and expectations that Immunodiagnostics and Molecular growth have outpaced competitive reality. UBS estimates adjusted EBIT 2026-27 are 4%-6% below consensus and forecasts lower EPS and revenue growth.
5 min readDiaSorin shares fell 3.8% to €73.68 after UBS downgraded the stock to “sell” from “neutral” and cut its price target by about 17% to €55. UBS cited rising competition and China policy headwinds in immunodiagnostics, plus execution risk for DiaSorin’s Liaison Nes platform in molecular diagnostics. UBS expects 2026 EBIT 4% to 6% below consensus.
2 min readSimply Wall St reports DiaSorin S.p.A. Q2 2026 sales of €315 million and net income of €46 million, broadly in line with the prior year. H1 2026 sales were €602 million and net income €84 million, down year on year. The article also cites a buyback program up to €250 million and discusses analyst expectations for 2029.
4 min read